Fatal Disseminated Candidiasis Due to Amphotericin-B-Resistant Candida guilliermondii
Authors: James D. Dick, Bruce R. Rosengard, William G. Merz, Robert K. Stuart, Grover M. Hutchins, Rein Saral
Journal: Annals of Internal Medicine (1985)

Brief Reports1 January 1985Fatal Disseminated Candidiasis Due to Amphotericin-B-Resistant Candida guilliermondiiJAMES D. DICK, Ph.D., BRUCE R. ROSENGARD, B.S., WILLIAM G. MERZ, Ph.D., ROBERT K. STUART, M.D., GROVER M. HUTCHINS, M.D., REIN SARAL, M.D.JAMES D. DICK, Ph.D., BRUCE R. ROSENGARD, B.S., WILLIAM G. MERZ, Ph.D., ROBERT K. STUART, M.D., GROVER M. HUTCHINS, M.D., REIN SARAL, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-102-1-67 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDisseminated candidiasis is a significant cause of morbidity and mortality in immunocompromised patients. Candida albicans is the commonest pathogen associated with systemic candidiasis, although other species do cause infections (1). Amphotericin B is the drug of choice for treatment of disseminated candidal infection, and the development of amphotericin B resistance is considered rare. We report the case of a patient with aplastic anemia who died from disseminated infection caused by a strain of C. guilliermondii that developed progressive resistance to amphotericin B.A 52-year-old white woman was admitted to The Johns Hopkins Oncology Center for evaluation and treatment of aplastic...References1. MEUNIER-CARPENTIERKIEHNARMSTRONG FTD. Fungemia in the immunocompromised host: changing patterns, antigenemia, high mortality. Am J Med. 1981;71:363-70. CrossrefMedlineGoogle Scholar2. MERZSANDFORD WG. Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol. 1979;9:677-80. CrossrefMedlineGoogle Scholar3. DICKMERZSARAL JWR. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158-63. CrossrefMedlineGoogle Scholar4. RIPPON J. Candidiasis and the pathogenic yeasts. In: RIPPON JW. Medical Mycology: The Pathogenic Fungi and the Pathogenic Actinomycetes. Philadelphia: W.B. Saunders Co.; 1982:565-94. Google Scholar5. HURLEYWINNER RH. Pathogenicity in the genus Candida. Mycopathologia. 1964;24:337-46. Google Scholar6. BODENHOFF J. Resistance studies of Candida albicans, with special reference to two patients subjected to prolonged antibiotic treatment. Odontol Tidskr. 1968;76:279-94. MedlineGoogle Scholar7. SAFESAFESUBDENMORRIS LSRD. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis. Can J Microbiol. 1977;23:398-401. CrossrefMedlineGoogle Scholar8. DRUTZLEHRER DR. Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function. Am J Med Sci. 1978;276:77-92. CrossrefMedlineGoogle Scholar9. PAPPAGIANISCOLLINSHECTORREMINGTON DMRJ. Development of resistance to amphotericin B in Candida lusitaniae infecting a human. Antimicrob Agents Chemother. 1979;16:123-6. CrossrefMedlineGoogle Scholar10. GUINETCHANASGOULLIERBONNEFOYAMBROISE-THOMAS RJAGP. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J Clin Microbiol. 1983;18:443-4. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: The Johns Hopkins Medical Institutions Baltimore, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByA comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promiseStigmasterol as a potential biomarker for amphotericin B resistance in Leishmania donovaniClinical features, antifungal susceptibility, and outcome of Candida guilliermondii fungemia: An experience in a tertiary hospital in mid-TaiwanAmphotericin B: Polyene Resistance MechanismsThe fungal resistome: a risk and an opportunity for the development of novel antifungal therapiesIn vitro susceptibility of amphotericin-B, voriconazole and caspofungin against Candida guilliermondii biofilms, isolated from dentals units water pipes, under different growth phasesCandida fermentati as a Cause of Persistent Fungemia in a Preterm Neonate Successfully Treated by Combination Therapy with Amphotericin B and CaspofunginTherapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcomeReferencesThe Epidemiology of Invasive CandidiasisLupus-like presentation and rare dual infections in an immunocompetent individualWhat do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeastKodamaea Ohmeri Fungemia in an Immunocompetent Patient Treated with Micafungin: Case Report and Review of the LiteratureResistance to Antifungal AgentsEpidemiology of Invasive Mycoses in North AmericaCandida Guilliermondii Fungemia in a Critically III Trauma PatientIn Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution MethodsRare and emerging Candida speciesPeptide antibiotics: An alternative and effective antimicrobial strategy to circumvent fungal infectionsAmphotericin B: Polyene Resistance MechanismsPolymerase chain reaction assay for specific identification of Candida guilliermondii (Pichia guilliermondii)Antifungal therapyReavaliação da suscetibilidade de Candida à anfotericina B: estudo comparativo com isolados de três hospitais do estado do Rio Grande do SulFungemia due to Candida guilliermondii in a pediatric and adult population during a 12-year periodEpidemiology of Invasive Candidiasis: a Persistent Public Health ProblemCandida guilliermondii , an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance ProgramInvasive Fungal Pathogens: Current Epidemiological TrendsKilling Kinetics of Caspofungin, Micafungin, and Amphotericin B against Candida guilliermondiiCandida guilliermondii Fungemia in Patients with Hematologic MalignanciesCandida guilliermondii as the aetiology of candidosisCandida guilliermondii isolated from HIV-infected human secretes a 50 kDa serine proteinase that cleaves a broad spectrum of proteinaceous substratesIn Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic MalignanciesRare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatusIn vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). In-vitro-Wirkung von Voriconazol (UK-109, 496), Fluconazol, Itraconazol und Amphotericin B gegen 132 Nicht-albicans-Hefepilzisolate aus dem Blut (CANARI-Studie)In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agentsManagement of Infection With Naturally Amphotericin B-Resistant FungiManagement of candidiasis Management of Candida species infections in critically ill patientsEvaluation of Etest Method for Determining Fluconazole and Voriconazole MICs for 279 Clinical Isolates of Candida Species Infrequently Isolated from BloodAntifungal agents of use in animal health - chemical, biochemical and pharmacological aspectsAntifungal Drug ResistanceIn Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from BloodAntifungal Resistance in Pathogenic FungiSensibilidad a antifúngicos de levaduras patógenas emergentesIn vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† †This study was presented, in part, at the 37th ICAAC in Toronto, Canada, 28th September – 1st October 1997.Agents for treatment of invasive fungal infectionsFungal InfectionsCorrelation between In Vitro Susceptibility Determined by E Test and Response to Therapy with Amphotericin B: Results from a Multicenter Prospective Study of CandidemiaAntifungal resistance in non- albicans Candida speciesEfficacy of LY303366 against Amphotericin B-Susceptible and -Resistant Aspergillus fumigatus in a Murine Model of Invasive AspergillosisClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug ResistanceClinical Pharmacology of Systemic Antifungal Agents: A Comprehensive Review of Agents in Clinical Use, Current Investigational Compounds, and Putative Targets for Antifungal Drug DevelopmentResistance to amphotericin B: emerging clinical and microbiological patternsCandida guilliermondii Infection in SCID Mice in Association with the Acceleration of the Elimination of Transfused Human Red Blood Cells.CLINICAL RELEVANCE OF ANTIFUNGAL RESISTANCEIdentification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysatesCandida infections in the ICUSecular Trends in the Epidemiology of Nosocomial Fungal Infections at a Teaching Hospital in Taiwan, 1981 to 1993Konstanz und Variabilität des Hefenachweises bei stationären Patienten: Ein Vergleich der Untersuchungsergebnisse von Rostock und DresdenThe changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceEmerging fungal infections in cancer patientsSusceptibility testing of fungi: current status of correlation of in vitro data with clinical outcomeRapid identification of Candida species by DNA fingerprinting with PCRAntifungal therapy in the oral cavityFUNGAL INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTSNew and emerging yeast pathogensComparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolatesResistance to Antifungal AgentsAre incremental doses of amphotericin B required for the treatment of visceral leishmaniasis?Management of Immunocompromised Patients with Evidence of an Invasive MycosisAntifungal susceptibility testingComparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicansIntroduction to CandidaFluconazole (Diflucan®): a reviewDemonstration of antibodies against Candida guilliermondii var. guilliermondii in asymptomatic infertile menOral CandidiasisSensibilidade de leveduras do gênero Candida, isoladas de pacientes com câncer, a antifúngicos poliênicosIn vitro activity of cloconazole, sulconazole, butoconazole, isoconazole, fenticonazole, and five other antifungal agents against clinical isolates of Candida albicans and Candida spp.Invasive Fungal Infections: Problems and Challenges for Developing New Antifungal CompoundsChemoprophylaxis of Fungal Infections in Granulocytopenic Patients Using Fluconazole vs Oral Amphotericin BCandida Guilliermondii Var. Guilliermondii Infection in Infertile CouplesTrichosporon beigelii, an emerging pathogen resistant to amphotericin BAn Infectious Disease Specialist's ViewpointManagement of Fungal Infections in Patients with Neoplastic DiseasesOpportunistic fungal infections in immunocompromised hostsCandidiasisPrefaceTreatment of systemic fungal infections: Recent progress and current problemsEsophageal candidiasisAmphotericin B-resistant yeast infection in severely immunocompromised patientsSkin rash associated withCandida guilliermondiiThe Genetics of Medically Important FungiMicrotiter broth dilution method for yeast susceptibility testing with validation by clinical outcomeSusceptibility of clinical isolates of yeasts to anti-fungal agentsEvaluation of Abbott Quantum II yeast identification systemImidazoles, Ketoconazole, Amphotericin B, and Candida guilliermondiiGARY WILSON, M.D., JAMES E. PEACOCK JR., M.D.Amphotericin B Resistance in CandidaJOHN F. FISHER, M.D., D. MARK HENSON, M.D.Resistance to Antifungal Agents 1 January 1985Volume 102, Issue 1Page: 67-68KeywordsAmphotericinCancer treatmentCandidiasisDrugsHematology and oncologyHospital medicineMorbidityMortalityPathogensResearch laboratories Issue Published: 1 January 1985 PDF DownloadLoading ...